Related Experiment Videos

Measles virus and C3 binding sites are distinct on membrane cofactor protein (CD46)

M Manchester1, A Valsamakis, R Kaufman

  • 1Department of Neuropharmacology, Scripps Research Institute, La Jolla, CA 92037.

Insights

Membrane cofactor protein (CD46) binds measles virus (MV) via its SCR1 and SCR2 domains, not the transmembrane or cytoplasmic regions. This finding identifies key viral binding sites on CD46 for potential therapeutic development.

Area of Science:

  • Virology
  • Immunology
  • Cell Biology

Background:

  • Membrane cofactor protein (CD46) is the cellular receptor for measles virus (MV).
  • Decay accelerating factor (DAF; CD55), a similar protein, does not bind MV.
  • Understanding the MV-CD46 interaction is crucial for antiviral strategies.

Purpose of the Study:

  • To pinpoint the specific domains of CD46 responsible for MV binding.
  • To investigate the role of different CD46 structural regions in MV receptor function.
  • To identify potential targets for inhibiting MV infection.

Main Methods:

  • Constructing CD46 mutants and CD46-DAF chimeric proteins.
  • Testing the susceptibility of engineered cells to MV infection.
  • Utilizing monoclonal antibodies (mAbs) against CD46 domains to block MV binding.

Main Results:

  • The extracellular domain of CD46, specifically SCR1 and SCR2, is essential for MV binding.
  • The transmembrane domain and cytoplasmic tail of CD46 are not required for MV receptor function.
  • Monoclonal antibodies targeting SCR1 or SCR2 blocked MV infection, while those targeting SCR3/SCR4 did not.

Conclusions:

  • The MV receptor determinant on CD46 resides within the SCR1 and SCR2 domains.
  • These findings provide a basis for developing therapeutics to inhibit MV binding and infection.
  • Targeting CD46's SCR1 and SCR2 domains offers a promising strategy against measles virus.

Related Concept Videos